Thursday, August 9, 2012
A team from GlaxoSmithKline plc and the Structural Genomics Consortium has identified the first selective and potent histone demethylase inhibitor and shown it dampens the macrophage
inflammatory response.1 The pharma now is exploring the therapeutic
applications of the inhibitor in autoimmune and inflammatory diseases.
Casting a wide net
"GSK continues to drive focused
validation efforts with GSK-J1 in a variety of in vitro and ex vivo
disease models, internally and through its collaborations," wrote
Kruidenier and Rab Prinjha, head of the EpiNova DPU, in a joint email to SciBX.
Kotz, J. SciBX 5(31);
Published online Aug. 9, 2012
1. Kruidenier, L. et al. Nature; published online July 29, 2012;
Contact: David M. Wilson, GlaxoSmithKline plc R&D,
2. De Santa, F. et al. Cell 130, 1083-1094
3. De Santa, F. et al. EMBO J. 28, 3341-3352
4. Nicodeme, E. et al. Nature 468, 1119-1123
5. Bouchie, A. &
Fulmer, T. BioCentury 20, A1-A5; Jan. 23,
AND INSTITUTIONS MENTIONED
Constellation Pharmaceuticals Inc., Cambridge, Mass.
EpiTherapeutics ApS, Copenhagen, Denmark
Epizyme Inc., Cambridge, Mass.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Structural Genomics Consortium, Oxford, U.K.
University of Copenhagen, Copenhagen, Denmark
University of Oxford, Oxford, U.K.